Cynthia Basu

557 total citations
24 papers, 382 citations indexed

About

Cynthia Basu is a scholar working on Oncology, Hematology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Cynthia Basu has authored 24 papers receiving a total of 382 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Hematology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Cynthia Basu's work include Multiple Myeloma Research and Treatments (11 papers), CAR-T cell therapy research (10 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Cynthia Basu is often cited by papers focused on Multiple Myeloma Research and Treatments (11 papers), CAR-T cell therapy research (10 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Cynthia Basu collaborates with scholars based in United States, Canada and Egypt. Cynthia Basu's co-authors include Alexander M. Lesokhin, Noopur Raje, Andrzej Jakubowiak, Michaël Sébag, Michael P. Chu, Moshe Levy, Suzanne Trudel, Andrew Dalovisio, Nizar J. Bahlis and Melhem Solh and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Cynthia Basu

21 papers receiving 370 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cynthia Basu United States	10	230	199	136	109	63	24	382
Marie-Anne Damiette Smit United States	7	261 1.1×	65 0.3×	64 0.5×	120 1.1×	44 0.7×	11	402
Ö. Ataman United Kingdom	14	313 1.4×	78 0.4×	48 0.4×	169 1.6×	28 0.4×	23	539
Edward L. Braud United States	7	148 0.6×	29 0.1×	70 0.5×	62 0.6×	107 1.7×	7	335
Aric C. Hall United States	8	202 0.9×	335 1.7×	27 0.2×	262 2.4×	15 0.2×	25	412
Lionel Karlin France	13	253 1.1×	308 1.5×	28 0.2×	237 2.2×	47 0.7×	45	444
Pierre Squifflet Belgium	12	214 0.9×	85 0.4×	24 0.2×	71 0.7×	97 1.5×	20	406
Raja Mudad United States	15	174 0.8×	107 0.5×	21 0.2×	44 0.4×	79 1.3×	35	435
Paul M. Diderichsen United States	10	119 0.5×	90 0.5×	24 0.2×	101 0.9×	45 0.7×	38	341
Bei Wang United States	10	261 1.1×	13 0.1×	219 1.6×	66 0.6×	47 0.7×	32	349
Vladimir Hanes United States	11	248 1.1×	16 0.1×	159 1.2×	27 0.2×	319 5.1×	40	385

Countries citing papers authored by Cynthia Basu

Since Specialization

Citations

This map shows the geographic impact of Cynthia Basu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cynthia Basu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cynthia Basu more than expected).

Fields of papers citing papers by Cynthia Basu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cynthia Basu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cynthia Basu. The network helps show where Cynthia Basu may publish in the future.

Co-authorship network of co-authors of Cynthia Basu

This figure shows the co-authorship network connecting the top 25 collaborators of Cynthia Basu. A scholar is included among the top collaborators of Cynthia Basu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cynthia Basu. Cynthia Basu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goel, Sanjay, Khalil Zaman, Ahmed Elkhanany, et al.. (2025). Abstract P5-08-28: Randomized phase 2 window of opportunity trial comparing the effect of preoperative atirmociclib (PF-07220060) plus letrozole versus letrozole alone on Ki-67 tumor expression in postmenopausal women with HR+/HER2+ breast cancer. Clinical Cancer Research. 31(12_Supplement). P5–8.

Yap, Timothy A., Erika Hamilton, Patricia LoRusso, et al.. (2024). 184MO First-in-human phase I/IIa study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 in combination with endocrine therapy (ET) in patients (pts) with HR+/HER2− metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitors (CDK4/6i): Safety and efficacy update. ESMO Open. 9. 103206–103206. 4 indexed citations

Giordano, Antonio, Anja Williams, Binghe Xu, et al.. (2024). First-in-human phase 1/2a study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 + endocrine therapy (ET): Updated safety data in patients with HR+/HER2− mBC.. Journal of Clinical Oncology. 42(16_suppl). 3108–3108. 1 indexed citations

Bahlis, Nizar J., Caitlin Costello, Noopur Raje, et al.. (2023). Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nature Medicine. 29(10). 2570–2576. 76 indexed citations

Yap, Timothy A., Antonio Giordano, Erika Hamilton, et al.. (2023). First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy.. Journal of Clinical Oncology. 41(16_suppl). 3009–3009. 13 indexed citations

Harding, James J., Ignacio Garrido‐Laguna, Xiaoying Chen, et al.. (2022). A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors. Frontiers in Immunology. 13. 845417–845417. 11 indexed citations

Yap, Timothy A., Cynthia Basu, Jonathan W. Goldman, et al.. (2022). Abstract P5-16-06: A first-in-human phase 1/2a dose escalation/expansion study of the first-in-class CDK2/4/6 inhibitor PF-06873600 alone or with endocrine therapy in patients with breast or ovarian cancer. Cancer Research. 82(4_Supplement). P5–16. 8 indexed citations

Raje, Noopur, Nizar J. Bahlis, Bhagirathbhai Dholaria, et al.. (2022). Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma. Blood. 140(Supplement 1). 388–390. 33 indexed citations

Jakubowiak, Andrzej, Nizar J. Bahlis, Noopur Raje, et al.. (2022). Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1.. Journal of Clinical Oncology. 40(16_suppl). 8014–8014. 11 indexed citations

10.

Solh, Melhem, Bhagirathbhai Dholaria, Cynthia Basu, et al.. (2021). EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA. Hematology Transfusion and Cell Therapy. 43. S195–S196. 2 indexed citations

11.

Sébag, Michaël, Noopur Raje, Nizar J. Bahlis, et al.. (2021). Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1. Blood. 138(Supplement 1). 895–895. 41 indexed citations

12.

Bahlis, Nizar J., Noopur Raje, Caitlin Costello, et al.. (2021). Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).. Journal of Clinical Oncology. 39(15_suppl). 8006–8006. 31 indexed citations

13.

Dholaria, Bhagirathbhai, Nizar J. Bahlis, Noopur Raje, et al.. (2021). OAB-026: MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM). Clinical Lymphoma Myeloma & Leukemia. 21. S17–S17. 1 indexed citations

14.

Pradhan, Vivek, et al.. (2021). Confidence Intervals for Discrete Data in Clinical Research. 1 indexed citations

15.

Lesokhin, Alexander M., Moshe Levy, Andrew Dalovisio, et al.. (2020). Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 136(Supplement 1). 8–9. 29 indexed citations

16.

Raje, Noopur, Andrzej Jakubowiak, Cristina Gasparetto, et al.. (2019). Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 134(Supplement_1). 1869–1869. 34 indexed citations

17.

Gamalo, Margaret, Cynthia Basu, Xin Zhao, et al.. (2017). Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation. Pharmaceutical Statistics. 16(4). 232–249. 56 indexed citations

18.

Kartha, Reena V., Richard C. Brundage, James C. Cloyd, et al.. (2016). A model‐based approach to assess the exposure–response relationship of Lorenzo's oil in adrenoleukodystrophy. British Journal of Clinical Pharmacology. 81(6). 1058–1066. 9 indexed citations

19.

Basu, Cynthia, Reena V. Kartha, Richard C. Brundage, et al.. (2016). A hierarchical Bayesian approach for combining pharmacokinetic/pharmacodynamic modeling and Phase IIa trial design in orphan drugs: Treating adrenoleukodystrophy with Lorenzo’s oil. Journal of Biopharmaceutical Statistics. 26(6). 1025–1039. 7 indexed citations

20.

Patil, Patil, et al.. (2010). Presentation and management of giant fibroid uterus in an adolescent girl. 13–13. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact